Cancer Gene Therapy Market to be Worth $8.70 Billion by 2030: Grand View Research, Inc.

News provided by

Oct 24, 2022, 07:00 ET

SAN FRANCISCO, Oct. 24, 2022 /PRNewswire/ -- The global cancer gene therapy market size is expected to reach USD 8.70 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to register a CAGR of 19.99% from 2022 to 2030 owing to the increasing demand for novel therapeutics globally and rising incidence of cancer cases globally. Moreover, this therapy offers an absolute solution to different kinds of inherited and induced cancer conditions, which makes it a more desired option for cancer therapeutics. For instance, Kite's Tecartus (brexucabtagene autoleucel) is approved by the FDA for the treatment of relapsed or refractory B-cell precursor acute lymphoblastic leukemia.

Key Industry Insights & Findings from the report:

The market is witnessing a key shift with the rise in gene level understanding of a cancer condition and rising need for gene induced immunotherapy and personalized medicine.
The gene induced immunotherapy segment held the largest share in 2021 due to increase in the advancement in gene induced immunotherapy research.
Biopharmaceutical companies held the largest market share in 2021 owing to rising demand for novel gene therapy and increasing number of FDA approvals for cancer gene therapy. Biopharmaceutical companies are anticipated to witness the fastest growth in the forecast period due to increasing research and development activities in the field.
North America dominated the market in 2021 due to the presence of key players and rising support from the government and National Cancer Institute to advance the research on oncology in the region.

Read 150-page full market research report for more Insights, "Cancer Gene Therapy Market Size, Share & Trends Analysis Report By Therapy (Oncolytic Virotherapy, Gene Induced Immunotherapy, Gene Transfer), By End-use, By Region, And Segment Forecasts, 2022 - 2030", published by Grand View Research.

Cancer Gene Therapy Market Growth & Trends

There is an increasing prevalence of malignant tumor cases across the globe, which is expected to propel the need for various strategies for effective treatment and to combat the increasing incidence of malignant tumors. Moreover, technological advancements in the market are expected to provide new opportunities for novel therapeutics. As a result, there is an increasing number of product approvals. For instance, in March 2022, European Medicine Agency recommended conditional marketing authorization for Carvykti (ciltacabtagene autoleucel) to be used for the treatment of subjects with relapsed and refractory multiple myeloma.

The market is positively driven by the lucrative support from the government and national cancer societies across the globe. There has been an increasing focus on increasing funds for research on cancer gene therapy. For instance, in December 2021, The Dutch platform called DARE-NL (in the Netherlands) has been awarded a USD 5.2 million grant from the KWF Dutch cancer society. The grant allows the DARE-NL to level up the availability of cell and gene therapy strategies accessible to the needy population.

The investment in new and complex technologies is relatively low for Asian manufacturers as they are more focused on less complex molecules that can be produced in bulk. Thus, the investment in high-yielding, low-cost technologies is an alternative for manufacturers in other developed regions such as Europe and North America to avoid competitive pressure.

Key players operating in the market are focusing on collaborations for the development of potent cancer gene therapy drugs. For instance, in August 2022, Gensaic signed a collaboration with Ovid Therapeutics for the development of up to three genetic medicines for central nervous system indications using its proprietary phage-derived particle gene therapy platform...

Cancer Gene Therapy Market Segmentation

Grand View Research has segmented the global cancer gene therapy market on the basis of therapy, end-use, and region

Cancer Gene Therapy Market - Outlook (Revenue, USD Million, 2018 - 2030)

Oncolytic Virotherapy
Gene Induced Immunotherapy
Gene Transfer

Cancer Gene Therapy Market - End-use Outlook (Revenue, USD Million, 2018 - 2030)

Research Institutes
Biopharmaceutical Companies
Diagnostic Centers
Others

Cancer Gene Therapy Market - Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

U.S.
Canada

Europe

U.K.
Germany
France
Spain
Italy

Asia Pacific

Japan
China
India
South Korea
Australia

Latin America

Brazil
Mexico
Argentina

Middle East & Africa

South Africa
Saudi Arabia
UAE

List of Key Players in the Cancer Gene Therapy Market

Abeona Therapeutics Inc.
Asklepios BioPharmaceutical Inc.
Altor Bioscience Inc.
Bluebird bio Inc.
BioCancell Inc.
CelgeneInc.
Elevate BioInc.
GlaxoSmithKlineInc.
Genelux Corporation
GenVec
Introgen TherapeuticsInc.
MerckKGaA
OncoGenex Pharmaceuticals Inc.

Check out more related studies published by Grand View Research:

Cancer Monoclonal Antibodies Market - The global cancer monoclonal antibodies market size is expected to reach USD 159.7 billion by 2030, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 11.2% from 2022 to 2030. The increasing prevalence of cancer, and product approvals along with a robust pipeline are the key factors augmenting the market growth. Furthermore, an increase in funding for R&D in this sector is expected to impact industrial growth. Moreover, the booming biosimilar market will further offer lucrative opportunities during the forecast period.
Tissue Engineering Market - The global tissue engineering market size is expected to reach USD 28.9 billion by 2027, expanding at a CAGR of 14.2%, according to a new report by Grand View Research, Inc. Allogenic tissue transplant method efficiently addresses challenges and limitations regarding the implementation and availability of autologous transplants. Moreover, the development of specialized procedures including implant fixing and sterilization to transform allogeneic implants so for application as biostatic implants is expected to drive revenue generation in this market.
FISH Probe Market - The global fluorescent in situ hybridization (fish) probe market size is expected to reach USD 1.04 billion by 2026, according to a new report by Grand View Research, Inc. It is projected to register a CAGR of 6.8% during the forecast period. Increasing global population prone to target diseases and demand for accurate and effective diagnostics of these diseases are the factors attributed to the growth. Increasing use of FISH probes in vitro diagnosis of various infectious diseases is expected to create growth opportunities in near future.

Browse through Grand View Research's Biotechnology Industry Research Reports.

About Grand View Research

Grand View Research, U.S.-based market research and consulting company, provides syndicated as well as customized research reports and consulting services. Registered in California and headquartered in San Francisco, the company comprises over 425 analysts and consultants, adding more than 1200 market research reports to its vast database each year. These reports offer in-depth analysis on 46 industries across 25 major countries worldwide. With the help of an interactive market intelligence platform, Grand View Research Helps Fortune 500 companies and renowned academic institutes understand the global and regional business environment and gauge the opportunities that lie ahead.

Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc.
Phone: 1-415-349-0058
Toll Free: 1-888-202-9519
Email: [email protected]
Web: https://www.grandviewresearch.com
Grand View Compass | Astra ESG Solutions
Follow Us: LinkedIn | Twitter